GlaxoSmithKline plc Stock Price and Value Analysis

Should you buy GlaxoSmithKline plc stock? (NYSE:GSK). Let's see how it does in our automated value investing analysis system.

  • This company has a large dividend yield!
  • This company has fluctuating growth.
  • This stock looks overpriced.
  • This company is not making money.
  • This company is less known than others.

GSK Free Cash Flow Trend

Hmm, we can't give any reliable projection for GlaxoSmithKline plc's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for GSK
Free Cash Flow trendline for GlaxoSmithKline plc

Inside the GSK Numbers

GSK Price
(GlaxoSmithKline plc stock price per share)
[?] PE Ratio versus Sector 123% higher than other Healthcare stocks
[?] PE Ratio versus Industry 163% higher than other Drug Manufacturers - Major stocks
[?] Cash Yield 1.87%
[?] Free Cash Flow Jitter 25%
[?] Dividend Yield 5%

Is GlaxoSmithKline plc Stock on Sale?

Based on our analysis, we believe that you should not buy GlaxoSmithKline plc right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy GSK Stock?

Does GlaxoSmithKline plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.